- About us
- Clinical trials
- News & Publications
Jens Hennecke joined SOTIO as Chief Business Officer in March 2015, where he is responsible for all aspects of partnering, M&A, investments, business intelligence and intellectual property.
Jens is a molecular biologist by training with 20 years of business and deal-making experience in the biopharmaceutical industry. Previously he served as Senior Vice President Business Development of Nasdaq-listed Micromet, Inc. During his 12-year tenure, Jens closed several corporate deals with pharma companies on Micromet’s T cell engagers BiTE, and was instrumental in the acquisition of Micromet by Amgen in 2012. Before joining SOTIO he had his own business consulting firm and has been serving as an advisor for European biotech companies. Jens also serves as a non-executive Director on the Board of NBE-Therapeutics AG in Basel, Switzerland.
Jens holds a diploma in biology from the University of Göttingen, Germany, and received his Ph.D. degree from the ETH Zürich, Switzerland. He also carried out postdoctoral research at Harvard University.